Nih perspectives on adverse event reporting looking to the future l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 42

NIH Perspectives on Adverse Event Reporting: Looking to the Future PowerPoint PPT Presentation


  • 157 Views
  • Uploaded on
  • Presentation posted in: General

NIH Perspectives on Adverse Event Reporting: Looking to the Future. VA IRB Chair Training Session April 8, 2004. NIH Mission. Discover new scientific knowledge that will improve human health NIH funds, conducts, and oversees biomedical research Over 50,000 extramural scientists

Download Presentation

NIH Perspectives on Adverse Event Reporting: Looking to the Future

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Nih perspectives on adverse event reporting looking to the future l.jpg

NIH Perspectives on Adverse Event Reporting: Looking to the Future

VA IRB Chair Training Session

April 8, 2004


Nih mission l.jpg

NIH Mission

  • Discover new scientific knowledge that will improve human health

  • NIH funds, conducts, and oversees biomedical research

    • Over 50,000 extramural scientists

      • Over 2,000 research institutions, including VA medical centers

    • Over 5,000 intramural scientists

      • 27 Institutes and Centers


Human subjects research l.jpg

Human Subjects Research:

NIH Roles

  • Conduct: Investigator

  • Fund: Sponsor

  • Oversee: Steward


Nih stewardship l.jpg

NIH Stewardship

  • Invest wisely taxpayer dollars entrusted to NIH for the support and conduct of biomedical research

  • To streamline and facilitate compliance with regulatory and administrative requirements for reporting clinical research information

  • Apply and communicate the knowledge gained from research

    • Improve design and conduct of studies

    • Advance development of new treatments and cures

    • Optimize patient safety


Nih roadmap l.jpg

NIH Roadmap

  • A coordinated plan to guide NIH research into the coming decade and beyond.


Re engineering the cr enterprise l.jpg

Re-engineering the CR Enterprise

  • Facilitate translational research

  • Enhanced training

  • Clinical Research Corps

  • Integration of CR networks/CR Informatics

    • Pilot NECTAR network

  • Harmonization of CR policies and processes


Clinical research navigating the roadway l.jpg

Clinical Research: Navigating the Roadway

  • Clinical research impeded by multiple and variable requirements to address fundamentally the same oversight concerns

    • Variability among and within agencies

      • Creates uncertainty about how to comply

      • Hampers efficiency and effectiveness


Clinical research policy analysis and coordination program l.jpg

Clinical Research Policy Analysis and Coordination Program

  • AIM

    • Promote clear, effective, and coordinated policies and regulations for the conduct and oversight of clinical research


Methods l.jpg

Methods

  • Work in concert with sibling agencies and research communities to catalyze the federal-wide coordination of policies pertaining to clinical research

  • Maintain the integrity and enhance effectiveness of federal and institutional systems of oversight

  • Develop tools and resources to facilitate understanding of and compliance with clinical research policies and requirements


Priority issues l.jpg

Priority Issues

  • Diverse adverse event reporting requirements

  • Confusion regarding roles and responsibilities of Data Safety and Monitoring Boards, IRBs, and other review mechanisms

  • Variable requirements for auditing and monitoring of clinical trials

  • Absence of uniform standards for electronic submission of safety and clinical research information


Priority issues11 l.jpg

Priority Issues

  • Confusion regarding applicability of privacy requirements and HIPAA to clinical research

  • Variability in interpretation of the human subjects regulations

  • Central vs. local IRB review

  • Best practices in informed consent

  • Investigator financial disclosure and conflicts of interest (COI)


Priority issues12 l.jpg

Priority Issues

  • Harmonize diverse adverse event reporting requirements

    • Identified as the highest priority among the many harmonization opportunities


Reporting safety information l.jpg

IRBs

IBCs

DSMBs

OHRP

NIH (various ICs)

FDA

Reporting Safety Information

  • All PIs conducting clinical research

  • submit adverse events reports, protocol amendments, and annual reports to a variety of localand federal entities:

  • Concern:

    • Diverse reporting requirements and formats


Challenges posed to clinical research l.jpg

Challenges Posed toClinical Research

  • Keeping track of multiple sets of requirements

  • Extra workload to report different information at different times to different agencies


Needs l.jpg

Needs

  • Promote understanding

  • Ease administrative burdens

  • Facilitate compliance

  • Enable robust analysis and communication of information

  • Enhance participant safety

  • Maximize knowledge


Diversity in adverse event reporting requirements l.jpg

Diversity in Adverse EventReporting Requirements

NIH has already taken an introspective look at the problem...


Nih working group on adverse event reporting l.jpg

NIH Working Group on Adverse Event Reporting

  • NIH conducted an “in-house” assessment of variability in AE reporting requirements

    • Established NIH Working Group on Adverse Event Reporting

    • First Step: Conducted survey of ICs


Nih ae working group findings l.jpg

NIH AE Working Group Findings

  • Compliant with the regulatory “floor” or baseline

  • Wide variation among and within ICS with respect to:

    • AE definitions

    • AE severity grading

    • Expedited reporting timeframes

    • Reporting formats used


Nih ae working group findings20 l.jpg

NIH AE Working GroupFindings

  • Variation is a tremendous obstacle for PIs, IRBs, and sponsors

  • NIH could make an important contribution were it to promote coordination and harmonization efforts


Harmonization of ae reporting gene therapy example l.jpg

Harmonization of AE Reporting:Gene Therapy Example

  • Prior to January 2002:

    • Principal Investigators had to report to NIH all serious adverse events immediately

    • At variance with FDA requirements (21 CFR 312)

  • Current harmonized requirement:

    • Possibly associated, unexpected events reported within 15 days - or within 7 days if fatal or life threatening

    • Scope, timeframe, and definitions for safety reporting are now the same for NIH and FDA


Future activities l.jpg

Future Activities

  • Setting up a “Trans-Agency Task Force on Adverse Events” through OHRP to:

    • Study range of variability between agencies,

    • Prioritize opportunities for harmonization, and

    • Identify core data sets for shared, baseline reporting requirements.


Priority issues23 l.jpg

Priority Issues

  • Develop standards for electronic submission of safety and clinical research information

    • Use of electronic systems to collect safety data

      • Facilitates investigator compliance and agency oversight

      • Facilitates data sharing

        • Common vocabularies and data transmission standards are essential to make this possible


Prevailing paradigm l.jpg

Prevailing Paradigm

  • Paper-based reporting systems

  • Uncontrolled, “individualized” medical vocabularies

  • Diverse reporting formats and templates

  • Transmission and comparison of data cumbersome


Moving toward a new paradigm l.jpg

Moving Toward a New Paradigm

  • Tools for streamlined and effective communication and analysis of safety data

    • One AE reporting format

    • Uniform “Core” data elements

    • Controlled medical vocabularies

    • On-line adverse event reporting

  • Objective: To facilitate

    • Investigator compliance

    • Agency oversight

    • Data sharing


Genetic modification clinical research information system l.jpg

Genetic Modification Clinical Research Information System

(GeMCRIS)

  • Serve as an analytic tool for NIH and FDA CBER

    • Facilitate the evaluation and analysis of safety information from all gene transfer clinical trials

  • Provide database reports that can be routed to diverse user groups

    • IRBs, local DSMBs, co-investigators

      http://www.gemcris.od.nih.gov


Broader utility l.jpg

Broader Utility

  • GeMCRIS adapted as an adverse event reporting system for NIH intramural clinical research

    • NIH CC’s Clinical Research Information System Adverse Events (CRIS-AE)

    • Launch December 2003

  • Being used as a model for an adverse event reporting system for extramural clinical research


  • Slide31 l.jpg

    ProtoType / CRIS-AE

    Automated Protocol Writing and Adverse Event Reporting

    Two Web-based systems:

    One user interface and “feel”


    Slide32 l.jpg

    Overview

    ProtoTypeCRIS-AE

    • An automated-system assist to:

    • Protocol writing and tracking

    • Standardized templates

    • Flexibility

    • Resource mapping

    • Leveraging protocol data for:

    • AE report writing

    • AE research support

      Automated assistance:

    • Report tracking


    Slide33 l.jpg

    Advantages for the IRB

    • Flexible workflow maybe tailored by organization.

    • Centralized system management.

      • Add, modify, inactivate users and organizations

      • Define user roles and security access

      • Update intervention reference tables (drugs, labs, radiology, etc.)

    • Immediate access to protocols and status:

      • Automated alerts for pending reviews, late AERs

    • Visibility of resource requirements:

      • High level cost estimates

      • Identify resource constraints


    Government efforts toward standardization l.jpg

    Government Efforts Toward Standardization

    • Data Standards

      • Government-wide standards for health information

        • e-Gov

          • CHI (vocabulary)

    • Universal Data Model

      • Overarching principles for adverse event reporting

        • 3500 (MedWatch report)

        • HL-7 data model

        • ICH data model

      • Goal: Streamlined, yet robust, data model


    Benefits of standardization for local oversight l.jpg

    Benefits of Standardization for Local Oversight

    • Improved electronic reporting to the IRB

    • Comparable language to describe a range of possible adverse events

    • More effective local management of adverse event data

    • Common adverse event reporting formats used by multiple sites

    • Facilitated analysis at the federal level

    • More efficient dissemination of federal findings to IRBs, PIs, and other at local level


    Clinical research informatics l.jpg

    Clinical Research Informatics

    • Another key NIH Roadmap initiative

    • Embodied in the National Electronic Clinical Trials and Research (NECTAR) Network

    • Provides the necessary infrastructure to advance coordination and harmonization

      • Research management tools

      • Connectivity between sites


    Nectar integration of clinical research networks l.jpg

    NECTAR: Integration of Clinical Research Networks

    Establish interoperable networks where clinical studies and trials can be effectively conducted


    Web based suite of tools for clinical research l.jpg

    Web-Based Suite of Tools for Clinical Research

    • Anticipated Functionality -- outcome of focus group meetings

      • Protocol Authoring Tool

      • IRB Review Management Tool

      • Adverse Event Reporting Tool

    • Development Process -- consultation and collaboration with other Federal agencies, IRB community, and Research communities to determine

      • Unified format and “core” data elements

      • Functions


    Harmonization establishing the foundation l.jpg

    Harmonization: Establishing the Foundation

    • Establish NIH program to provide concentrated attention to critical coordination and harmonization concerns

    • Create facile and efficient mechanisms for coordinating and collaborating with VA and other agencies

    • Conduct broad and ongoing stakeholder consultation (including IRBs) through:

      • Ad hoc expert panels

      • Focus groups

      • Education and outreach


    Future challenges l.jpg

    Future Challenges

    • Addressing multiple needs

      • Many constituencies affected

      • Needs of each community may not be fully consonant

      • Continued input and consultation will be key

    • Catalyzing change

      • Inertia

      • Investment in current agency practices

      • Coordination


    Overarching principles l.jpg

    Overarching Principles

    • Elimination of unnecessary obstacles to the efficient and safe conduct of clinical research

    • Optimizing protections for research participants through a more coordinated, streamlined system of oversight


  • Login